Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy

MET is a driver oncogene in non-small-cell lung cancer (NSCLC), and its amplification is associated with acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A 56-year-old Japanese male with lung adenocarcinoma harboring an EGFR exon 21 L858R mutation received e...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Katsuhiro Yoshimura, MD, Naoki Inui, MD, PhD, Masato Karayama, MD, PhD, Yusuke Inoue, MD, Noriyuki Enomoto, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Yutaro Nakamura, MD, PhD, Kengo Takeuchi, MD, PhD, Haruhiko Sugimura, MD, PhD, Takafumi Suda, MD, PhD
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2017-01-01
Serier:	Respiratory Medicine Case Reports
Fag:	Crizotinib Erlotinib MET amplification Non-small-cell lung cancer Resistance
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2213007117300308
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!